Fagan Associates’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-139,954
| Closed | -$3.71M | – | 135 |
|
|
2024
Q4 | $3.71M | Sell |
139,954
-2,019
| -1% | -$54.8K | 0.59% | 50 |
|
|
2024
Q3 | $4.11M | Buy |
141,973
+134,513
| +1,803% | +$3.92M | 0.69% | 45 |
|
|
2024
Q2 | $209K | Buy |
+7,460
| New | +$205K | 0.04% | 112 |
|
|
2023
Q2 | – | Sell |
-61,209
| Closed | -$2.5M | – | 122 |
|
|
2023
Q1 | $2.5M | Sell |
61,209
-1,184
| -2% | -$51.1K | 0.62% | 42 |
|
|
2022
Q4 | $3.2M | Buy |
62,393
+51,397
| +467% | +$2.46M | 0.85% | 33 |
|
|
2022
Q3 | $481K | Buy |
10,996
+1
| +0% | +$49 | 0.13% | 87 |
|
|
2022
Q2 | $576K | Buy |
10,995
+202
| +2% | +$10.3K | 0.15% | 83 |
|
|
2022
Q1 | $559K | Sell |
10,793
-598
| -5% | -$31K | 0.11% | 95 |
|
|
2021
Q4 | $673K | Buy |
11,391
+1,606
| +16% | +$79.6K | 0.13% | 90 |
|
|
2021
Q3 | $421K | Buy |
9,785
+1,321
| +16% | +$58.5K | 0.09% | 96 |
|
|
2021
Q2 | $331K | Buy |
8,464
+1,085
| +15% | +$42.2K | 0.07% | 110 |
|
|
2021
Q1 | $267K | Buy |
7,379
+975
| +15% | +$34.6K | 0.06% | 114 |
|
|
2020
Q4 | $236K | Buy |
+6,404
| New | +$235K | 0.06% | 110 |
|
|
2020
Q1 | – | Sell |
-6,146
| Closed | -$228K | – | 114 |
|
|
2019
Q4 | $228K | Sell |
6,146
-132
| -2% | -$4.7K | 0.07% | 112 |
|
|
2019
Q3 | $214K | Sell |
6,278
-105
| -2% | -$3.82K | 0.08% | 111 |
|
|
2019
Q2 | $262K | Buy |
6,383
+933
| +17% | +$37K | 0.11% | 103 |
|
|
2019
Q1 | $220K | Buy |
5,450
+105
| +2% | +$4.21K | 0.09% | 105 |
|
|
2018
Q4 | $221K | Buy |
5,345
+32
| +0.6% | +$1.33K | 0.11% | 101 |
|
|
2018
Q3 | $222K | Buy |
+5,313
| New | +$205K | 0.09% | 111 |
|
|
2018
Q1 | – | Sell |
-38,801
| Closed | -$1.33K | – | 107 |
|
|
2017
Q4 | $1.33K | Buy |
38,801
+382
| +1% | +$13K | 0.54% | 52 |
|
|
2017
Q3 | $1.3M | Buy |
38,419
+3,544
| +10% | +$114K | 0.64% | 50 |
|
|
2017
Q2 | $1.11M | Sell |
34,875
-208
| -0.6% | -$6.56K | 0.58% | 54 |
|
|
2017
Q1 | $1.14M | Sell |
35,083
-51,241
| -59% | -$1.62M | 0.63% | 48 |
|
|
2016
Q4 | $2.66M | Sell |
86,324
-183
| -0.2% | -$5.59K | 1.54% | 23 |
|
|
2016
Q3 | $2.78M | Buy |
86,507
+4,185
| +5% | +$140K | 1.7% | 19 |
|
|
2016
Q2 | $2.75M | Buy |
82,322
+4,165
| +5% | +$133K | 1.77% | 19 |
|
|
2016
Q1 | $2.2M | Buy |
+78,157
| New | +$2.23M | 1.46% | 23 |
|
|
2014
Q3 | – | Sell |
-42,036
| Closed | -$1.18M | – | 89 |
|
|
2014
Q2 | $1.18M | Sell |
42,036
-194
| -0.5% | -$5.53K | 1.01% | 34 |
|
|
2014
Q1 | $1.29M | Buy |
+42,230
| New | +$1.26M | 1.11% | 33 |
|
Other funds holding PFE
TIM
Fagan Associates's PFE Position: Q1 2025 in Review
Fagan Associates sold out of Pfizer (PFE) in Q1 2025, closing a stake of 139,954 shares — an estimated $3.71M sold.
Fagan Associates first reported a position in PFE in Q1 2014 and held it in 29 quarters. The position peaked at $4.11M in Q3 2024. 2,931 funds tracked by Wall St. Rank hold PFE as of Q1 2025.
- Fagan Associates reported no remaining Pfizer position as of Q1 2025 after selling out during the quarter.
- Fagan Associates sold 139,954 Pfizer shares in Q1 2025, an estimated $3.71M.
- Fagan Associates first reported a position in Pfizer in Q1 2014 and held it in 29 quarters.
- Fagan Associates's Pfizer position peaked at $4.11M in Q3 2024.
- 2,931 funds tracked by Wall St. Rank held Pfizer as of Q1 2025.
Based on Fagan Associates's 13F filing for Q1 2025, filed 6 May 2025.